Healthcare - Biotechnology - NASDAQ - GB
$ 16.0
-8.57 %
$ 1.81 B
Market Cap
-10.32
P/E
CASH FLOW STATEMENT
-160 M
OPERATING CASH FLOW
-127 M
INVESTING CASH FLOW
21.1 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Centessa Pharmaceuticals plc
| Net Income | -151 M |
| Depreciation & Amortization | 810 K |
| Capital Expenditures | -169 K |
| Stock-Based Compensation | 29.4 M |
| Change in Working Capital | -18.9 M |
| Others | -10.2 M |
| Free Cash Flow | -161 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (151.1) | (216.2) | (381.9) | (10.7) | (5.1) |
| Depreciation & Amortization | 0.8 | 0.1 | 34 K | 0 | 6 K |
| Deferred Income Tax | (26.5) | (2.9) | (6.8) | 0 | 770 |
| Stock Based Compensation | 29.4 | 25.0 | 14.9 | 0.3 | 0.2 |
| Other Operating Activities | 6.0 | (3.7) | 257.8 | 0.2 | 770 |
| Change in Working Capital | (18.9) | (2.8) | (5.4) | (0.5) | (1.0) |
| Cash From Operations | (160.3) | (200.5) | (136.1) | (10.6) | (5.8) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.2) | (1.1) | (0.2) | 0 | 0 |
| Other Items | (126.8) | 0.2 | 63.4 | 0 | 0 |
| Cash From Investing Activities | (127.0) | (0.9) | 63.2 | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 12 K | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 73.9 | 1.4 | 3.8 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 0.5 | 586.1 | 1 K | 5.2 |
| Cash From Financing Activities | 21.1 | 0.5 | 660.1 | 1.4 | 9.0 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (265.6) | (201.4) | 590.1 | (9.3) | 3.7 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (160.5) | (201.7) | (136.3) | (10.6) | (5.8) |